The 36-month beta value for LEXX is also noteworthy at 1.09. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LEXX is 16.18M, and at present, short sellers hold a 3.18% of that float. The average trading volume of LEXX on January 14, 2025 was 153.29K shares.
LEXX) stock’s latest price update
Lexaria Bioscience Corp (NASDAQ: LEXX) has seen a decline in its stock price by -13.95 in relation to its previous close of 2.06. However, the company has experienced a -18.69% decline in its stock price over the last five trading sessions. accesswire.com reported 2025-01-14 that Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3 (the “Study”), comparing an oral version of DehydraTECH-processed Zepbound® (“DehydraTECH-tirzepatide”) to conventional injected Zepbound®. The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.
LEXX’s Market Performance
Lexaria Bioscience Corp (LEXX) has seen a -18.69% fall in stock performance for the week, with a -24.25% decline in the past month and a -42.82% plunge in the past quarter. The volatility ratio for the week is 9.81%, and the volatility levels for the past 30 days are at 8.73% for LEXX. The simple moving average for the past 20 days is -18.71% for LEXX’s stock, with a -37.89% simple moving average for the past 200 days.
LEXX Trading at -20.41% from the 50-Day Moving Average
After a stumble in the market that brought LEXX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.12% of loss for the given period.
Volatility was left at 8.73%, however, over the last 30 days, the volatility rate increased by 9.81%, as shares sank -22.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.91% lower at present.
During the last 5 trading sessions, LEXX fell by -19.72%, which changed the moving average for the period of 200-days by -52.83% in comparison to the 20-day moving average, which settled at $2.18. In addition, Lexaria Bioscience Corp saw -15.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LEXX starting from CHRISTOPHER RICHARD, who purchase 27,172 shares at the price of $2.47 back on Dec 03 ’24. After this action, CHRISTOPHER RICHARD now owns 50,000 shares of Lexaria Bioscience Corp, valued at $67,175 using the latest closing price.
CHRISTOPHER RICHARD, the Chief Executive Officer of Lexaria Bioscience Corp, purchase 22,828 shares at $2.24 during a trade that took place back on Dec 02 ’24, which means that CHRISTOPHER RICHARD is holding 22,828 shares at $51,217 based on the most recent closing price.
Stock Fundamentals for LEXX
Current profitability levels for the company are sitting at:
- -14.7 for the present operating margin
- 0.96 for the gross margin
The net margin for Lexaria Bioscience Corp stands at -14.73. The total capital return value is set at -0.77. Equity return is now at value -108.31, with -109.08 for asset returns.
Based on Lexaria Bioscience Corp (LEXX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -49.75. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -7304690.0.
Currently, EBITDA for the company is -5.68 million with net debt to EBITDA at 1.09. When we switch over and look at the enterprise to sales, we see a ratio of 46.35. The receivables turnover for the company is 1.89for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 29.64.
Conclusion
In summary, Lexaria Bioscience Corp (LEXX) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
